|
|
|
| Survival analysis of chemotherapy and Targeted therapy for patients with advanced non-small-cell lung cancer and EGFR mutated-unknown |
| ZHANG Chongguo1 WANG Jirong1 LI Juan1 WANG Keming1 WANG Zhaoxia1 LI Yadong2 |
1.Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University, Jiangsu Province, Nanjing 210011, China;
2.Department of Thoracic Surgery, the Second Affiliated Hospital of Nanjing Medical University, Jiangsu Province, Nanjing 210011, China |
|
|
|
Abstract Objective To compare and analyze the overall survival (OS) of patients with advanced non-small-cell lung cancer and EGFR mutated-unknown after the treatment of EGFR-TKI and intercalated combination of chemotherapy and EGFR-TKI. Methods Clinical data of 58 patients with advanced histopathology confirmed non-small-cell lung cancer and EGFR mutated-unknown treated in the Second Affiliated Hospital of Nanjing Medical University from January 2010 to December 2014 was analyzed retrospectively. 36 patients were treated with intercalated combination of chemotherapy and EGFR-TKIs (rotational therapy group) and 22 patients were treated with chemotherapy alone (chemotherapy group). The survival rate was calculated by Kaplan-Meier method and compared by Log-rank test. Cox single and multivariate prognosis analysis was performed. Results 22 patients received chemotherapy, the median age was 28 years, the mean age was 30.444 (*) ± 5.122.36 patients received intercalated combination of chemotherapy and EGFR-TKI, the median age was 36 years, the mean age was 42.740 (*) ± 3.668. There was significant difference in OS between the intercalated combination of chemotherapy and EGFR-TKIs and chemotherapy groups (P=0.0413). Drug treatment modalities was the only predictor of OS (P=0.047, 0.008), while cigarette smoking, age, pathology, and sex were not (P > 0.05). Conclusion Intercalated combination of chemotherapy and EGFR-TKIs treatment is better than chemotherapyin the advanced non-small-cell lung cancer with EGFR mutated-unknown.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancer Statistics，2017 [J]. CA Cancer J Clin，2017，67（1）:7-30.
[2] Novello S，Barlesi F，Califano R，et al. Metastatic non-small-cell lung cancer：ESMO ClinicalPractice Guidelines for diagnosis，treatment andfollow-up [J]. Annals of Oncology，2016，27（Supplement 5）：v1-v27.
[3] Chermiti Ben Abdallah F，Ben Ali G，Sadok Boudaya M，et al. Treatment and prognosis of advanced stage non-small-cell lung cancer [J]. Rev Mal Respir，2014，31（3）：214-220.
[4] Zhao N，Zhang XC，Yan HH，et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR：a meta-analysis of randomized controlled clinical trials [J]. Lung Cancer，2014，85（1）：66-73.
[5] Greenhalgh J，Dwan K，Boland A，et al. First-line treatment of advanced epidermal growth factor receptor（EGFR） mutation positive non-squamous non-small cell lung cancer [J]. Cochrane Database Syst Rev，2016，25（5）：CD010383.
[6] Goss GD，Spaans JN. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung [J]. Oncologist，2016，21（2）：205-213.
[7] Cabanero M，Sangha R，Sheffield BS，et al. Management of EGFR-mutated non-small-cell lung cancer：practical implications from a clinical and pathology perspective [J]. Curr Oncol，2017，24（2）：111-119.
[8] Tan DS，Yom SS，Tsao MS，et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer：Status in 2016 [J]. J Thorac Oncol，2016，11（7）：946-963.
[9] Zhang K，Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer [J]. J Cancer Res Ther，2016，12（Supplement）：C131-C137.
[10] Chen Y，Yang J，Li X，et al. First-line epidermal growth factor receptor（EGFR）-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma [J]. Cancer Sci，2016，107（12）：1800-1805．
[11] Xue C，Hu Z，Jiang W，et al. National survey of the medical treatment status for non-small cell lung cancer（NSCLC） in China [J]. Lung Cancer，2012，77（2）：371-375.
[12] Zhou C，Yao LD. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer：Review of the Literature [J]. J Thorac Oncol，2016，11（2）：174-186.
[13] Tan PS，Lopes G，Acharyya S，et al. Bayesian network meta-comparison of maintenance treatments for stage Ⅲb/Ⅳ non-small-cell lung cancer（NSCLC） patients with good performance status not progressing after first-line induction chemotherapy：results by performance status，EGFR mutation，histology and response to previous induction [J]. Eur J Cancer，2015，51（16）：2330-2344.
[14] Tan CS，Cho BC，Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer [J]. Lung Cancer，2016，93：59-68.
[15] Soejima K，Yasuda H，Hirano T. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer [J]. Expert Rev Clin Pharmacol，2017，10（1）：31-38.
[16] Zhang K，Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer [J]. J Cancer Res Ther，2016，12（Supplement）：C131-C137.
[17] Seki Y，Fujiwara Y，Kohno T，et al. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors [J]. Oncologist，2016 ，21（2）：156-164.
[18] Wu YL，Lee JS，Thongprasert S，et al.Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer（FASTACT-2）：a randomised，double-blind trial[J].Lancet Oncol. 2013，14（8）：777-786.
[19] Quoix E，Westeel V，Moreau L，et al. Second-line therapy in elderly patients with advanced nonsmallcell lung cancer [J]. Eur Respir J，2014，43（1）：240-249. |
|
|
|
